Clinical trialNCT01505608TerminatedPhase 1/PHASE2Interventional

Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma

SponsorGiselle ShollerEnrollment14Neuroblastoma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this research study is to evaluate a new investigational drug (TPI 287) for early relapsed neuroblastoma. An investigational drug is one that has not yet been approved by the Food and Drug Administration. This investigational drug is called TPI 287. This study will look at the tumor's response to the study drug, TPI 287, in combination with Irinotecan and Temozolomide versus the combination of Irinotecan and Temozolomide alone. This study will also evaluate the safety and tolerability of the study drug, TPI 287.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Don Eslin, MD
Arnold Palmer Hospital for Children
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Phoenix Children'S Hospital
Phoenix, Arizona, United States
Rady Children'S Hospital
San Diego, California, United States
Connecticut Children'S Hospital
Hartford, Connecticut, United States
Arnold Palmer Hospital for Children- Md Anderson
Orlando, Florida, United States
Helen Devos Children'S Hospital
Grand Rapids, Michigan, United States
Children'S Mercy Hospitals and Clinics
Kansas City, Missouri, United States
Cardinal Glennon Children'S Medical Center
St Louis, Missouri, United States
Levine Children'S Hospital
Charlotte, North Carolina, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Irinotecan →TPI-287Temozolomide →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Dec 2011
Primary completion: 31 Dec 2014
Completion: 31 Dec 2014
Last update posted: 6 Aug 2024
Registered enrollment: 14
Registry id: NCT01505608

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.